SAN FRANCISCO, Aug. 10 /PRNewswire/ -- Aperio Healthcare, Inc. (http://www.aperiohc.com/), a San Francisco-based marketing communications and creative services firm, has been named agency of record by DNA 2.0, Inc., a leader in custom gene synthesis and protein engineering. Based in Menlo Park, DNA 2.0 is a biotechnology company, developer of two platform technologies, the DNA-2-Go(TM) gene synthesis process and DeNovo Genes(TM), a protein engineering and sequence optimization technology. The firm's charter is to exploit the synergy between a highly efficient gene synthesis process and new protein optimization technologies.
"DNA 2.0 exists to simplify the steps between thinking of an experiment and doing it. We were impressed by Aperio's depth of knowledge and creativity. We believe their team is a perfect fit to help us with the creative strategy we needed to bring DNA 2.0 into the next phase by communicating both the complexity of our technology and the simplicity of our solutions," said Jeremy Minshull, Ph.D., President of DNA 2.0, Inc.
San Francisco-based Aperio Healthcare was launched in 2003 to serve the marketing communication needs of the emerging life sciences industry. "We knew from inception that we had the right blend of experience and capabilities to produce effective campaigns and target a newer breed of companies in the life sciences technology market," said Sylvia Ventura, Managing Director of Aperio Healthcare. "Our team members bring an interesting mix of high-tech and healthcare experience in both the B2B and the consumer areas. Our business model delivers on the budget scale of new ventures. Our approach has been extremely well received, and we have seen terrific success this year. It just confirms that our offering is right on time."
The engagement with Aperio will include the development of the DNA 2.0 global corporate brand identity, and the promotional launch for DNA 2.0's two flagship products DNA-2-Go(TM) and DeNovo Genes(TM).
Aperio Healthcare recently added public relations services to its core competencies, and broadened its client base beyond California. The firm plans announcement of additional campaign successes and customer enrollments during the last quarter of 2004.
About DNA 2.0, Inc.
DNA 2.0 is applying its DeNovo Genes(TM) platform technology to design and produce information-rich gene variants. These gene variants are synthesized individually and then tested for functional activity. The data is analyzed and mapped as a mega dimensional projection of the correlated sequence-function space. The DeNovo Genes(TM) technology is uniquely suited to engineering proteins for commercial applications such as industrial biocatalysis and therapeutic polypeptide and polynucleotide optimization. For more information please visit http://www.dnatwopointo.com/ or email firstname.lastname@example.org.
About Aperio Healthcare, Inc.
Aperio Healthcare is a full service marketing communications and advertising agency based in San Francisco, California. The firm offers strategic counsel and marketing communications in four key sectors: genomics/drug discovery; biotechnology/pharmaceuticals; medical device/diagnostics; and consumer health. Aperio's services include campaign planning, positioning and brand strategy, public relations, advertising, and creative services. For additional information please visit http://www.aperiohc.com/, or call 415-601-5336.
Aperio Healthcare, Inc.